First Allied Advisory Services’s Teva Pharmaceuticals TEVA Stock Holding History

First Allied Advisory Services’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$326K	Buy	36,179 +12,467	+53%	+$132K	0.01%	869
2020 Q2	$292K	Sell	23,712 -1,786	-7%	-$20.2K	0.01%	848
2020 Q1	$229K	Buy	25,498 +205	+0.8%	+$2.1K	0.01%	878
2019 Q4	$251K	Sell	25,293 -354	-1%	-$3.16K	0.01%	1014
2019 Q3	$166K	Sell	25,647 -17,365	-40%	-$133K	0.01%	1143
2019 Q2	$397K	Buy	43,012 +4,262	+11%	+$51.4K	0.01%	770
2019 Q1	$617K	Sell	38,750 -653	-2%	-$11.5K	0.02%	607
2018 Q4	$618K	Sell	39,403 -2,269	-5%	-$46.5K	0.02%	546
2018 Q3	$906K	Buy	41,672 +6,733	+19%	+$156K	0.03%	497
2018 Q2	$840K	Sell	34,939 -2,176	-6%	-$44.4K	0.03%	505
2018 Q1	$645K	Buy	37,115 +321	+0.9%	+$6.27K	0.02%	575
2017 Q4	$689K	Sell	36,794 -2,526	-6%	-$38K	0.03%	547
2017 Q3	$697K	Buy	39,320 +3,413	+10%	+$76.8K	0.03%	513
2017 Q2	$1.18M	Sell	35,907 -258	-0.7%	-$7.99K	0.05%	372
2017 Q1	$1.15M	Sell	36,165 -497	-1%	-$17K	0.06%	330
2016 Q4	$1.33M	Buy	36,662 +3,226	+10%	+$129K	0.07%	310
2016 Q3	$1.54M	Buy	33,436 +507	+2%	+$26.5K	0.08%	260
2016 Q2	$1.66M	Buy	32,929 +701	+2%	+$37.3K	0.09%	246
2016 Q1	$1.71M	Buy	32,228 +1,513	+5%	+$88.8K	0.1%	232
2015 Q4	$2.01M	Buy	30,715 +2,596	+9%	+$160K	0.1%	222
2015 Q3	$1.59M	Buy	28,119 +1,382	+5%	+$89.6K	0.09%	263
2015 Q2	$1.58M	Buy	26,737 +802	+3%	+$49.5K	0.07%	305
2015 Q1	$1.61M	Buy	25,935 +7,565	+41%	+$440K	0.11%	227
2014 Q4	$1.06M	Buy	18,370 +1,563	+9%	+$87.1K	0.08%	306
2014 Q3	$902K	Buy	16,807 +1,309	+8%	+$69.3K	0.07%	318
2014 Q2	$800K	Sell	15,498 -5,926	-28%	-$303K	0.06%	387
2014 Q1	$1.12M	Sell	21,424 -3,471	-14%	-$160K	0.08%	269
2013 Q4	$1M	Sell	24,895 -149,621	-86%	-$5.89M	0.08%	290
2013 Q3	$6.62M	Buy	174,516 +31,809	+22%	+$1.24M	0.39%	65
2013 Q2	$5.65M	Buy	+142,707	New	+$5.56M	0.45%	41

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

First Allied Advisory Services's TEVA Position: Q3 2020 in Review

First Allied Advisory Services increased its Teva Pharmaceuticals (TEVA) stake by 53% in Q3 2020, buying an estimated $132K and bringing the position to 36,179 shares worth $326K. The position accounts for 0.01% of the portfolio, ranked #869.

First Allied Advisory Services first reported a position in TEVA in Q2 2013 and has held it in 30 quarters since. The position peaked at $6.62M in Q3 2013. 443 funds tracked by Wall St. Rank hold TEVA as of Q3 2020.

First Allied Advisory Services held 36,179 shares of Teva Pharmaceuticals worth $326K as of Q3 2020.
First Allied Advisory Services bought 12,467 Teva Pharmaceuticals shares in Q3 2020, an estimated $132K.
Teva Pharmaceuticals made up 0.01% of First Allied Advisory Services's portfolio in Q3 2020, its #869 holding.
First Allied Advisory Services first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 30 quarters since.
First Allied Advisory Services's Teva Pharmaceuticals position peaked at $6.62M in Q3 2013.
443 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2020.

Based on First Allied Advisory Services's 13F filing for Q3 2020, filed 13 Nov 2020.